/ Search

Search the archive.

Full-text across every dispatch: headlines, hooks, analysis, keywords, firms, and practice areas.

2 results for “CMA”
Jones DayAntitrust / Competition2026-08-06
UK Proposes Sweeping Reforms to Competition Class Actions, Appeals and CMA Enforcement

UK in-house counsel defending collective proceedings or facing CMA investigations must weigh in by 25 September 2026 on proposals that would tighten class certification, grant civil immunity to first-in leniency applicants, and consolidate regulatory appeals before the CAT.

On 17 July 2026, the UK Department for Business and Trade opened a consultation proposing wide-ranging reforms to three pillars of the competition landscape. For collective actions before the Competition Appeal Tribunal, certification would shift from a relative to an absolute suitability test, filing fees tied to claim value would be introduced, costs budgets would become mandatory, and damages-based funding agreements would be permitted for the first time in opt-out cases. The CAT would gain new mediation powers, and Type A leniency applicants would receive civil immunity from damages claims—a potentially decisive shift in cartel strategy. On regulatory appeals, the government proposes transferring jurisdiction from the CMA to the CAT, harmonising appeal standards across Ofwat, CAA, Ofcom and other sector regulators, and applying judicial review principles uniformly. On enforcement, the CMA would gain discretion over its decision-making structure, confidentiality handling and access-to-file rules, with a new £300,000 penalty cap for undertakings lacking representative turnover. Aff

Read the full dispatch →
Jones DayAntitrust / Competition2026-07-18
Cross-Border Merger Remedies Demand Coordinated Divestiture Strategies

Multinational deal teams must align remedy packages across FTC, DOJ, EC, and UK CMA reviews to avoid conflicting divestiture obligations.

Rising parallel enforcement by the FTC, DOJ, European Commission, and UK CMA is forcing merging parties to negotiate overlapping but inconsistent remedies—divestiture buyers, asset scopes, and timing often diverge by jurisdiction. Recent matters show agencies rarely defer to one another's analyses, increasing the risk that a remedy accepted in one forum triggers non-compliance in another. Practitioners recommend early pre-clearance mapping of likely remedy demands, harmonized purchaser searches, and explicit carve-outs in consent decrees to preserve flexibility. In-house counsel should build cross-border remedy playbooks before signing, identify jurisdiction-specific deal-breakers, and engage local counsel in parallel to stress-test divestiture commitments against each agency's stated preferences and recent precedent.

Read the full dispatch →

Stay ahead

Join the digest.

One email when the daily AmLaw 100 briefing ships. No noise, no pitch decks — just the grade 4–5 signal.